News >

Frontline Afatinib Shows Promise in EGFR+ NSCLC

Danielle Ternyila
Published: Monday, May 20, 2019

Antonio Passaro, MD, PhD
Antonio Passaro, MD, PhD
Afatinib (Gilotrif) was found to have clinical activity and be well tolerated in patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), which is consistent with data from the LUX-Lung (LL) 3/6 trials comparing frontline afatinib to standard chemotherapy in a similar patient population, according to results from a phase IIIb interim analysis.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication